Neonatal extra-corporeal life support: indications and limitations.
Cardiac extra-corporeal life support is used more frequently in the current era of complex, high-risk neonatal heart surgery. Although outcome for neonates with complex heart disease has improved in the last decade, thanks to advances in surgery and intensive care, survival in the subset that require extra-corporeal support remains unchanged at below 40%. Neonatal cardiac extra-corporeal support is a technically challenging therapy that is applied in a range of contexts including: post-operative low cardiac output syndrome, cardiac arrest, high-risk interventional catheterisation or as a bridge to recovery from dysrhythmia and myocarditis. Extra-corporeal life support has increased in particular for neonates with single ventricle disease in the last 5 years, mainly achieving similar results to biventricular patients. Further research is required in order to determine the optimal methods for patient selection and to establish important predictors of outcome including the longterm neurological development of survivors.
Brown
Kate L
KL
Cardiac Intensive Care Unit, Great Ormond Street Hospital for Sick Children, Great Ormond Street, London WC1N 3JH, UK. brownk@gosh.nhs.uk
Goldman
Allan P
AP
D015199:Extracorporeal Membrane Oxygenation / Q000379:methods*; D006330:Heart Defects, Congenital / Q000175:diagnosis / Q000601:surgery / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans; D007231:Infant, Newborn